Professor Richard Scolyer Dies After Fighting Brain Cancer
Professor Richard Scolyer Dies After Fighting Brain Cancer
Richard Scolyer 教授在對抗腦癌後逝世
Introduction
Professor Richard Scolyer was a famous doctor in Australia. He died at age 59. He had brain cancer for three years.
Richard Scolyer 教授是一位在澳洲著名的醫生。他在 59 歲時逝世，此前患有腦癌三年。
Main Body
Professor Scolyer helped many people with skin cancer. He found new medicines. These medicines helped more people live longer.
Scolyer 教授幫助了許多皮膚癌患者。他發現了新藥，讓更多人能夠延長壽命。
In 2023, he got brain cancer. He tried a new treatment on himself. He used three drugs and a special vaccine. This was a test to see if it worked.
在 2023 年，他患上腦癌。他在自己身上嘗試了一種新療法，使用了三種藥物和一種特殊疫苗。這是一次測試，以確認其成效。
The treatment did not cure him, but it gave doctors new information. Now, doctors in the USA and Australia are using this information to help other patients.
雖然該療法未能治癒他，但為醫生提供了新資訊。現在美國和澳洲的醫生正利用這些資訊來幫助其他患者。
The government gave 5.9 million dollars for brain cancer research. They started a new research position in his name to find more cures.
政府撥款 590 萬美元用於腦癌研究。他們還以他的名義設立了一個新的研究職位，以尋找更多治癒方法。
Conclusion
Professor Scolyer died, but he helped find new ways to fight brain cancer.
Scolyer 教授雖然逝世，但他幫助人們找到了對抗腦癌的新方法。
Vocabulary Learning
🕒 Talking about the Past
In the story, we see a pattern: He + action word (ending in -ed). This tells us something happened and is now finished.
Look at these changes:
- Help helped
- Try tried
- Use used
💡 The "Not" Rule
To say something is negative in the past, we use did not (or didn't) + the normal word. We do NOT add "-ed" here.
❌ The treatment did not cured him. ✅ The treatment did not cure him.
🔑 Key Vocabulary for A2
| Word | Simple Meaning |
|---|---|
| Research | Studying something to find a truth |
| Cure | To make a sick person healthy again |
| Treatment | The medicine or care a doctor gives |
Vocabulary Learning
The Death of Professor Richard Scolyer and Its Impact on Brain Cancer Research
理查德·斯科利爾教授逝世及其對腦瘤研究的影響
Introduction
Professor Richard Scolyer, a famous pathologist and former Australian of the Year, has died at the age of 59 after three years of treatment for glioblastoma, a type of brain cancer.
著名病理學家、前澳洲年度人物理查德·斯科利爾教授在治療了三年的膠質母細胞瘤（一種腦瘤）後，於59歲時逝世。
Main Body
Professor Scolyer was well-known for his important work in melanoma research, particularly as a leader at the Melanoma Institute of Australia. Working with Professor Georgina Long, he helped change how advanced melanoma is treated by using combination immunotherapy. This approach significantly increased the five-year survival rate from about 5% to 55%. Because of his expertise in this field, he used similar immunotherapy methods when he was diagnosed with glioblastoma in 2023.
斯科利爾教授以其在黑色素瘤研究中的重要工作而聞名，特別是在澳洲黑色素瘤研究所擔任領導者期間。他與 Georgina Long 教授合作，透過使用組合免疫療法，協助改變了晚期黑色素瘤的治療方式。這種方法將五年生存率從約 5% 顯著提高至 55%。由於他在該領域的專業知識，當他在 2023 年被診斷出患有膠質母細胞瘤時，他也採用了類似的免疫療法。
Since this specific cancer usually has a very poor outlook, Professor Scolyer decided to be the first patient in an experimental treatment plan. He received three immunotherapy drugs and a personalized vaccine before having surgery, which was different from the standard medical process. Although the cancer returned in early 2025, the data from his case led to a new clinical trial in the United States and Australia. This trial aims to find out if using immunotherapy before surgery can improve results for other patients.
由於這種特定的癌症通常預後非常不理想，斯科利爾教授決定成為一項實驗性治療計劃的首位患者。他在手術前接受了三種免疫藥物和一種個人化疫苗，這與標準的醫療流程不同。儘管癌症在 2025 年初復發，但他個案的數據促成了美國和澳洲的一項新臨床試驗。該試驗旨在研究手術前使用免疫療法是否能改善其他患者的結果。
In response to his work, the federal government provided a $5.9 million grant to create the Richard Scolyer Chair in Brain Cancer Research at Chris O'Brien Lifehouse. This project is intended to speed up research and make clinical trials more available. Furthermore, Professor Scolyer showed his commitment to science by publishing his results in the journal Nature Medicine and continuing to advocate for patients until his death.
為了回應他的貢獻，聯邦政府提供了 590 萬澳元的撥款，在 Chris O'Brien Lifehouse 設立「理查德·斯科利爾腦瘤研究講座教授」席位。此項目旨在加速研究並提高臨床試驗的可近性。此外，斯科利爾教授在《自然醫學》期刊發表其結果，並在去世前持續為患者發聲，展現了他對科學的奉獻。
Conclusion
Professor Scolyer has passed away, but he leaves behind a legacy of valuable medical data and increased government funding for brain cancer research.
斯科利爾教授雖然逝世，但他留下了寶貴的醫療數據，並增加了政府對腦瘤研究的資金支持。
Vocabulary Learning
🚀 The 'Power-Up' Shift: From Basic to Professional
As an A2 student, you usually say things like: "He did a lot of work" or "The government gave money." This is correct, but B2 students use precise verbs to show exactly how something happened.
Let's look at the "Professional Upgrades" found in this text:
💎 Upgrade 1: Instead of "Gave" Provided
- A2: The government gave a grant.
- B2: The government provided a grant.
- Why? "Provide" sounds formal and official. Use it when talking about services, money, or information.
💎 Upgrade 2: Instead of "Make faster" Speed up
- A2: This project will make research faster.
- B2: This project is intended to speed up research.
- Why? This is a phrasal verb. B2 speakers use these to sound more natural while remaining precise.
💎 Upgrade 3: Instead of "Help" Advocate for
- A2: He helped patients.
- B2: He continued to advocate for patients.
- Why? To "advocate" means to publicly support a cause. It describes a specific kind of help—speaking up for others.
💡 Pro Tip: The 'Result' Connection
Notice how the author links ideas. An A2 student uses "and" or "so." A B2 student uses phrases like "led to".
"the data from his case led to a new clinical trial"
Instead of saying "He had data so there was a trial," use led to to show a direct cause-and-effect chain. This makes your English sound like a bridge between a student and a professional.
Vocabulary Learning
Decease of Professor Richard Scolyer and the Resultant Implications for Neuro-Oncological Research
Richard Scolyer 教授逝世及其對神經腫瘤學研究的影響
Introduction
Professor Richard Scolyer, a distinguished pathologist and former Australian of the Year, has died at age 59 following a three-year period of treatment for glioblastoma.
著名病理學家兼前澳洲年度人物 Richard Scolyer 教授在治療膠質母細胞瘤三年後，以 59 歲之齡逝世。
Main Body
Professor Scolyer's professional trajectory was characterized by significant contributions to melanoma pathology, specifically through his leadership at the Melanoma Institute of Australia. In collaboration with Professor Georgina Long, he facilitated a paradigm shift in the treatment of advanced melanoma, utilizing combination immunotherapy to increase the five-year survival rate from approximately 5% to 55%. This expertise in immunotherapy served as the foundation for his own clinical intervention following a 2023 diagnosis of IDH 'wild' type glioblastoma.
Scolyer 教授的職業生涯以對黑色素瘤病理學的重大貢獻而聞名，特別是他於澳洲黑色素瘤研究所（Melanoma Institute of Australia）領導期間的成就。他與 Georgina Long 教授合作，促使進階黑色素瘤的治療方法發生範式轉移，利用組合免疫療法將五年生存率從約 5% 提升至 55%。這些在免疫療法方面的專業知識，為他在 2023 年被診斷出 IDH 「野生型」膠質母細胞瘤後採取的臨床干預奠定了基礎。
Given the poor prognosis associated with this specific malignancy—where median survival is typically 14 months—Scolyer elected to serve as the primary subject for an experimental protocol. This regimen involved the administration of three immunotherapy drugs and a personalized cancer vaccine prior to surgical debulking, a sequence that deviated from the established standard of care. While the malignancy recurred in early 2025, the data derived from his case provided the empirical basis for a subsequent clinical trial initiated in the United States and planned for Australia. This trial seeks to determine if pre-surgical immunotherapy can be systematized to improve outcomes for glioblastoma patients.
鑑於這種特定惡性腫瘤的預後較差——中位生存期通常僅為 14 個月——Scolyer 選擇擔任一項實驗方案的主要受試者。該方案涉及在手術減瘤前施用三種免疫治療藥物及一種個性化癌症疫苗，此順序與既定的標準治療有所偏差。儘管腫瘤於 2025 年初復發，但從其案例中獲得的數據，為隨後在美國啟動並計劃在澳洲推行的臨床試驗提供了實證基礎。該試驗旨在確定術前免疫療法是否能系統化，以改善膠質母細胞瘤患者的預後。
Institutional and governmental responses to Scolyer's work include the establishment of the Richard Scolyer Chair in Brain Cancer Research at Chris O'Brien Lifehouse, supported by a $5.9 million federal grant. This initiative is designed to accelerate research and expand clinical trial accessibility. Furthermore, Scolyer's commitment to scientific transparency was evidenced by the publication of his treatment outcomes in the journal Nature Medicine and his continued participation in physical endurance events and public advocacy until his death.
機構與政府對 Scolyer 研究工作的回應包括在 Chris O'Brien Lifehouse 設立「Richard Scolyer 腦癌研究教授席」，並獲聯邦政府資助 590 萬美元。此舉旨在加速研究並擴大臨床試驗的可及性。此外，Scolyer 對科學透明度的承諾，體現於他將治療結果發表在《自然醫學》（Nature Medicine）期刊，以及直到逝世前仍持續參與體能耐力賽與公開倡議。
Conclusion
Professor Scolyer has died, leaving a legacy of expanded clinical data and increased federal funding for brain cancer research.
Scolyer 教授逝世，留下了擴展的臨床數據以及增加的聯邦腦癌研究資助。
Vocabulary Learning
The Architecture of Nominalization & High-Density Lexical Chaining
To move from B2 to C2, a student must shift from narrating events to conceptualizing processes. The provided text exemplifies Nominalization—the linguistic process of turning verbs and adjectives into nouns to create a dense, objective, and academic tone.
⚡ The 'Verb-to-Noun' Pivot
Observe the transformation of action into entity:
- Standard B2: "He led the institute and helped change how melanoma is treated." C2 Masterclass: "...characterized by significant contributions... facilitated a paradigm shift."
By replacing the verb "change" with the noun phrase "paradigm shift," the writer ceases to describe a simple action and instead describes a theoretical phenomenon. This is the hallmark of C2 academic writing: the ability to treat complex ideas as static objects for analysis.
🔍 Deciphering Lexical Chaining
C2 proficiency requires recognizing "chains" of specialized terminology that maintain thematic cohesion without repetitive pronouns. Note the progression here:
Malignancy Experimental protocol Regimen Standard of care Empirical basis Clinical trial.
Each term doesn't just replace the previous one; it refines the scope. We move from the biological entity (malignancy) to the methodology (protocol/regimen) to the scientific validation (empirical basis).
🛠️ Stylistic Precision: The 'C2 Modifier'
B2 students use general adjectives (e.g., important, very bad). C2 writers use precise qualifiers that dictate the exact nature of the noun:
- "IDH 'wild' type" (Technical precision)
- "Surgical debulking" (Procedural precision)
- "Scientific transparency" (Abstract precision)
Pro Tip for Mastery: To emulate this, stop asking "What happened?" and start asking "What is the name of the process that happened?" If you can name the process (e.g., instead of saying "the funding increased," say "the expansion of clinical trial accessibility"), you are operating at a C2 level.